The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Open accessPublished version of a preprint
Abstract
Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient–derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we found that PDO therapeutic profiles paralleled patient outcomes and that PDOs enabled longitudinal assessment of chemosensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemosensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemorefractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection. Significance: New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for patients with pancreatic cancer. Combined genomic, transcriptomic, and therapeutic profiling of PDOs can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses, and facilitate precision medicine for patients with pancreatic cancer. Cancer Discov; 8(9); 1112–29. ©2018 AACR. See related commentary by Collisson, p. 1062. This article is highlighted in the In This Issue feature, p. 1047
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“114 PDO cultures from 101 patients were generated127 and subjected to transcriptomic profiling, followed by therapeutic profiling”
From Human disease models in drug development (2023) · cites this paper as [127]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The treatment outcome of the PDOs positively correlated with individual patient responses”
From Human disease models in drug development (2023) · cites this paper as [127]
The cited source says what the claim attributes to it.
In the citing paper
“patient-derived tumoroid models also show promise in testing drug efficacy and potentially determining a personalized treatment for the patient7–12.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This heterogeneity in treatment responses is now being exploited for the treatment of cystic fibrosis patients191, with a large ongoing European multicentre clinical trial study, led by the HIT-Cystic Fibrosis consortium, to identify potential responders214.”
From Organoids (2022) · cites this paper as [214]
Experimental — accuracy not yet measuredIn the citing paper
“Recently, normal and tumor organoid models have been developed from both human and mouse pancreas (82, 83).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [83]
In the citing paper
“Furthermore, with recent technological advancements (e.g. organoid models and conditionally reprogrammed cell lines), a new generation of cancer cell models is being derived to allow full representation of the histopathological and molecular diversity of tumours (37–42).”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,037
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Cited by
Sorted by citations
Items 301–400 of 1,001
Importance of Organoids for Personalized Medicine
Perkhofer, L., Frappart, P., Müller, M., & Kleger, A. (2018) · Personalized Medicine · doi:10.2217/pme-2018-0071 · Cited by 40
Functional Drug Screening in the Era of Precision Medicine
Napoli, G. C., Figg, W. D., & Chau, C. H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.912641 · Cited by 41
Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities
Paassen, I., Williams, J. S., Arceo, C. R., Ringnalda, F. C. A. S., Mercer, K., Buhl, J. L., Moreno, N., Federico, A., Franke, N. E., Kranendonk, M. E. G., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02681-y · Cited by 40
Self-citationJohnson, J., Sharick, J. T., Skala, M. C., & Li, L. (2019) · Journal of Mass Spectrometry · doi:10.1002/jms.4452 · Cited by 37
Hong, H. K., Yun, N. H., Jeong, Y., Park, J., Doh, J., Lee, W. Y., & Cho, Y. B. (2021) · Cancer Medicine · doi:10.1002/cam4.4114 · Cited by 37
Peschke, K., Jakubowsky, H., Schäfer, A., Maurer, H. C., Lange, S., Orben, F., Bernad, R., Harder, F. N., Eiber, M., Öllinger, R., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114876 · Cited by 37
Targeting cancer drug resistance utilizing organoid technology
Chai, C., Ji, P., Xu, H., Tang, H., Wang, Z., Zhang, H., & Zhou, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114098 · Cited by 35
Li, Y., Tang, S., Wang, H., Zhu, H., Lu, Y., Zhang, Y., Guo, S., He, J., Li, Y., Zhang, Y., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.008 · Cited by 45
Bian, B., Juiz, N. A., Gayet, O., Bigonnet, M., Brandone, N., Roques, J., Cros, J. F., Wang, N., Dusetti, N., & Iovanna, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00475 · Cited by 36
Górski, J., Zhang, Z., McCorkle, J. R., DeJohn, J., Wang, C., Miller, R. W., Gallion, H. H., Dietrich, C. S., Ueland, F. R., & Kolesar, J. (2021) · Biomedicines · doi:10.3390/biomedicines9081021 · Cited by 34
Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models
Gündel, B., Liu, X., Löhr, M. J., & Heuchel, R. L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.741162 · Cited by 38
Decellularized normal and cancer tissues as tools for cancer research
Gentilin, E., D’Angelo, E., Agostini, M., & Astolfi, L. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00398-2 · Cited by 37
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
Malinova, A., Veghini, L., Real, F. X., & Corbo, V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795251 · Cited by 39
Tao, M., & Wu, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02139-7 · Cited by 35
Pitter, K. L., Grbovic-Huezo, O., Joost, S., Singhal, A., Blum, M., Wu, K., Holm, M., Ferrena, A., Bhutkar, A. J., Hudson, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1742 · Cited by 35
Self-citationKang, Y., Deng, J., Ling, J., Li, X., Chiang, Y., Koay, E. J., Wang, H., Burks, J. K., Chiao, P. J., Hurd, M. W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151604 · Cited by 34
A mucus production programme promotes classical pancreatic ductal adenocarcinoma
Tonelli, C., Yordanov, G. N., Hao, Y., Deschênes, A., Hinds, J., Belleau, P., Klingbeil, O., Brosnan, E., Doshi, A., Park, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-329839 · Cited by 34
Self-citationBaker, L. A., Tiriac, H., & Tuveson, D. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8879-2_9 · Cited by 34
Self-citationRamaker, R. C., Hardigan, A. A., Gordon, E. R., Wright, C., Myers, R., & Cooper, S. J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08388-1 · Cited by 33
Waters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 34
Self-citationm6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance
Chen, C., Guo, Y., Guo, Y., Wu, X., Si, C., Xu, Y., Kang, Q., & Sun, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.746789 · Cited by 35
Lead identification using 3D models of pancreatic cancer
Fernández-Vega, V., Hou, S., Plenker, D., Tiriac, H., Baillargeon, P., Shumate, J., Scampavia, L. D., Seldin, J., Souza, G. R., Tuveson, D. A., et al. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.03.002 · Cited by 35
Self-citationMoving the Needle on Precision Medicine in Pancreatic Cancer
O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34
Self-citationGao, J., Lan, J., Liao, H., Yang, F., Qiu, P., Jin, F., Wang, S., Shen, L., Chao, T., Zhang, C., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11434-9 · Cited by 37
A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
Fukamachi, H., Kim, S., Koh, J., Lee, H. S., Sasaki, Y., Yamashita, K., Nishikawaji, T., Shimada, S., Akiyama, Y., Byeon, S., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1121-3 · Cited by 33
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 32
Driehuis, E., Oosterom, N., Heil, S. G., Muller, I. B., Lin, M., Kolders, S., Jansen, G., de Jonge, R., Pieters, R., Clevers, H. C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231588 · Cited by 37
Self-citationKazi, A., Chen, L., Xiang, S., Vangipurapu, R., Yang, H., Beato, F., Fang, B., Williams, T. M., Husain, K. M., Underwood, P. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4781 · Cited by 33
Favorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9
Kinny‐Köster, B., Habib, J. R., Wolfgang, C. L., He, J. P., & Javed, A. A. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-426 · Cited by 34
Self-citationEpigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
Orben, F., Lankes, K., Schneeweis, C., Hassan, Z., Jakubowsky, H., Krauß, L., Boniolo, F., Schneider, C., Schäfer, A., Murr, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.151353 · Cited by 36
Geevimaan, K., Guo, J.-Y., Shen, C., Jiang, J., Fann, C. S. J., Hwang, M., Shui, J., Lin, H.-T., Wang, M.-J. S., Shih, H.-C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.883437 · Cited by 34
Zhao, Y., Zhang, B., Ma, Y., Zhao, F., Chen, J., Wang, B., Jin, H., Zhou, F., Guan, J., Zhao, Q., et al. (2022) · Advanced Science · doi:10.1002/advs.202201539 · Cited by 34
Genomic heterogeneity in pancreatic cancer organoids and its stability with culture
Usman, O. H., Zhang, L., Xie, G., Kocher, H. M., Hwang, C., Wang, Y. J., Mallory, X., & Irianto, J. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00342-9 · Cited by 36
Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening
Zhang, S., Shen, J., Wang, X., Sun, X., Wu, Y., Zhang, M., Wang, R., & Hu, K. (2023) · Open Research (University of Surrey) · doi:10.1002/viw.20230010 · Cited by 33
MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer
Klingbeil, O., Skopelitis, D. S., Tonelli, C., Yoshimoto, T., Alpsoy, A., Panepinto, M. C., Minicozzi, F., Merrill, J. R., Cafiero, A. M., Aggarwal, D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1529 · Cited by 31
Self-citationAutomation of Organoid Cultures: Current Protocols and Applications
Louey, A., Hernández, D., Pébay, A., & Daniszewski, M. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211024547 · Cited by 33
Shinkawa, T., Ohuchida, K., & Nakamura, M. (2022) · Cancers · doi:10.3390/cancers14163994 · Cited by 32
Mapping oncogenic protein interactions for precision medicine
Tabar, M. S., Francis, H., Yeo, D., Bailey, C. G., & Rasko, J. E. J. (2022) · International Journal of Cancer · doi:10.1002/ijc.33954 · Cited by 30
Lencioni, G., Gregori, A., Toledo, B., Rebelo, R., Immordino, B., Amrutkar, M., Xavier, C. P. R., Kocijancic, A., Pandey, D. P., Perán, M., et al. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.002 · Cited by 32
Tumor Microenvironment–Responsive Peptide-Based Supramolecular Drug Delivery System
Zhang, W., Yu, L., Ji, T., & Wang, C. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00549 · Cited by 31
Organoid technology for personalized pancreatic cancer therapy
Bengtsson, A., Andersson, R. E., Rahm, J., Ganganna, K., Andersson, B., & Ansari, D. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00585-1 · Cited by 34
Weng, N., Qin, S., Liu, J., Huang, X., Jiang, J., Zhou, L., Zhang, Z., Xie, N., Wang, K., Jin, P., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.018 · Cited by 32
Lumibao, J. C., Okhovat, S. R., Peck, K. L., Lin, X., Lande, K., Yomtoubian, S., Ng, I., Tiriac, H., Lowy, A. M., Zou, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.172419 · Cited by 30
Self-citationInhibiting stromal Class I HDACs curbs pancreatic cancer progression
Liang, G., Oh, T. G., Hah, N., Tiriac, H., Shi, Y., Truitt, M., Antal, C. E., Atkins, A. R., Li, Y., Fraser, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42178-6 · Cited by 32
Self-citationLi, P., Huang, M., Ma, Y., Zhang, Y., & Shi, C. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03628-3 · Cited by 32
Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi, C., Roessler, S. K., Kruk, B., Lammert, F., Krawczyk, M. J., & Andersen, J. B. (2019) · Liver International · doi:10.1111/liv.14085 · Cited by 31
Bolck, H. A., Pauli, C., Göbel, E., Mühlbauer, K., Dettwiler, S., Moch, H., & Schraml, P. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00246 · Cited by 30
Lee, J. H., Kim, H., Lee, S. H., Ku, J., Chun, J. W., Seo, H., Kim, S., Paik, W. H., Ryu, J. K., Lee, S. K., et al. (2021) · Gut and Liver · doi:10.5009/gnl210166 · Cited by 34
Toward reproducible tumor organoid culture: focusing on primary liver cancer
Guo, L., Li, C., & Gong, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1290504 · Cited by 34
Chang, C., Liu, F., Militi, S., Hester, S. S., Nibhani, R., Deng, S., Dunford, J. E., Rendek, A., Soonawalla, Z. F., Fischer, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47680-z · Cited by 31
Merrill, N. M., Kaffenberger, S. D., Bao, L., Vandecan, N. M., Goo, L., Apfel, A. M., Cheng, X., Qin, Z., Liu, C.-J., Bankhead, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.05.026 · Cited by 35
Current methods in translational cancer research
Lee, M. W., Miljanic, M., Triplett, T., Ramírez, C., Aung, K. L., Eckhardt, S., & Capasso, A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09931-5 · Cited by 32
Diehl, J. N., Klomp, J. E., Snare, K. R., Hibshman, P. S., Blake, D. R., Kaiser, Z. D., Gilbert, T. S. K., Baldelli, E., Pierobon, M., Papke, B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101335 · Cited by 30
Chen, K., Ma, Y., Zhong, X., Lan, J., Di, L., Tian, X., Yang, Y., & Yang, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216586 · Cited by 28
Kalla, J., Pfneissl, J., Mair, T., Tran, L., & Egger, G. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00960-8 · Cited by 31
Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives
Qiao, D., Wang, R. C., & Wang, Z. (2025) · Cells · doi:10.3390/cells14221804 · Cited by 39
Raffenne, J., Nicolle, R., Puleo, F., Corre, D. L., Boyez, C., Maréchal, R., Emile, J., Demetter, P., Bardier–Dupas, A., Laurent‐Puig, P., et al. (2019) · Cancers · doi:10.3390/cancers11111808 · Cited by 28
Zhan, X., Nie, X., Gao, F., Zhang, C., You, Y., & Yu, Y. (2020) · Biomaterials Science · doi:10.1039/d0bm01324b · Cited by 28
Gao, M., Harper, M. M., Lin, M., Qasem, S. A., Patel, R. A., Mardini, S. H., Gabr, M. M., Cavnar, M. J., Pandalai, P. K., & Kim, J. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.11.009 · Cited by 29
Self-citationMiyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28
Self-citationPancreatic Organoids for Regenerative Medicine and Cancer Research
Casamitjana, J., Espinet, E., & Rovira, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.886153 · Cited by 29
Kokumai, T., Omori, Y., Ishida, M., Ohtsuka, H., Mizuma, M., Nakagawa, K., Maeda, C., Ono, Y., Mizukami, Y., Miura, S., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100102 · Cited by 28
Wang, T., Tang, Y., Pan, W., Yan, B., Hao, Y., Zeng, Y., Chen, Z., Lan, J., Zhao, S., Deng, C., et al. (2023) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002511 · Cited by 28
Hsieh, Y., Liu, T., Chou, C.-J., Chen, H., Lee, K., & Yang, P. (2019) · Genes · doi:10.3390/genes10100766 · Cited by 29
LaComb, J. F., Plenker, D., Tiriac, H., Bucobo, J. C., D'Souza, L. S., Khokhar, A. S., Patel, H., Channer, B., Joseph, D. F., Wu, M., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.02.045 · Cited by 28
Self-citationS100 family proteins are linked to organoid morphology and EMT in pancreatic cancer
Low, R. R. J., Fung, K. Y., Gao, H., Preaudet, A., Dagley, L. F., Yousef, J. M., Lee, B., Emery‐Corbin, S. J., Nguyen, P. M., Larsen, R. H., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01126-z · Cited by 29
Patient-derived organoids: a promising tool for breast cancer research
Shi, Y., Guan, Z., Cai, G., Nie, Y., Zhang, C., Luo, W., & Liu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1350935 · Cited by 29
Ubhi, T., Zaslaver, O., Quaile, A. T., Plenker, D., Cao, P. M., Pham, N., Békési, A., Jang, G.-H., O'Kane, G. M., Notta, F., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00742-z · Cited by 27
Self-citationGiron‐Michel, J., Padelli, M., Oberlin, E., Guénou, H., & Duclos‐Vallée, J. (2025) · BioDrugs · doi:10.1007/s40259-024-00702-0 · Cited by 31
The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J. (2022) · Cancers · doi:10.3390/cancers14092144 · Cited by 27
Jeong, Y. J., Knútsdóttir, H., Shojaeian, F., Lerner, M. G., Wissler, M. F., Henriet, E., Ng, T., Datta, S., Navarro-Serer, B., Chianchiano, P. E., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162054 · Cited by 27
Self-citationOrganoid: Bridging the gap between basic research and clinical practice
Weng, G., Tao, J., Liu, Y., Qiu, J., Su, D., Wang, R., Luo, W., & Zhang, T. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216353 · Cited by 29
Hallmark discoveries in the biology of Wilms tumour
Perotti, D., Williams, R. D., Wegert, J., Brzezinski, J. J., Maschietto, M. C., Ciceri, S., Gisselsson, D., Gadd, S., Walz, A. L., Furtwängler, R., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00824-0 · Cited by 29
CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids
Hennig, A., Wolf, L., Jahnke, B., Polster, H., Seidlitz, T., Werner, K., Aust, D. E., Hampe, J., Distler, M., Weitz, J., et al. (2019) · Stem Cells International · doi:10.1155/2019/1024614 · Cited by 27
Ding, J., Xie, Y., Liu, Z., Zhang, Z., Ni, B., Yan, J., Zhou, T., & Hao, J. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.10.042 · Cited by 26
Pancreatic Progenitors and Organoids as a Prerequisite to Model Pancreatic Diseases and Cancer
Hohwieler, M., Müller, M., Frappart, P., & Heller, S. (2019) · Stem Cells International · doi:10.1155/2019/9301382 · Cited by 27
Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Gao, C., Wisniewski, L., Liu, Y., Staal, B., Beddows, I., Plenker, D., Aldakkak, M., Hall, J., Barnett, D., Gouda, M. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2475 · Cited by 26
Self-citationAdjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021
Turpin, A., Amrani, M. E., Bachet, J., Pietrasz, D., Schwarz, L., & Hammel, P. R. (2020) · Cancers · doi:10.3390/cancers12123866 · Cited by 26
Yu, Y., Zhu, Y.-J., Xiao, Z., Chen, Y., Chang, X., Liu, Y., Tang, Q., & Zhang, H. (2022) · Biomarker Research · doi:10.1186/s40364-022-00421-0 · Cited by 27
Cutoff value of IC50 for drug sensitivity in patient-derived tumor organoids in colorectal cancer
Tang, Y., Wang, T., Hu, Y., Ji, H., Yan, B., Hu, X., Zeng, Y., Hao, Y., Xue, W., Chen, Z., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107116 · Cited by 26
Zeöld, A., Sándor, G. O., Kiss, A. L., Soós, A. Á., Tölgyes, T., Bursics, A., Szűcs, Á., Harsányi, L., Kittel, Á., Gézsi, A., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03703-8 · Cited by 29
Overcoming limitations in current measures of drug response may enable AI-driven precision oncology
Ovchinnikova, K., Born, J., Chouvardas, P., Rapsomaniki, M., & Julio, M. K. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00583-0 · Cited by 26
Lee, S., Kim, K., Lee, E., Lee, K., Ahn, K. H., Park, H., Kim, Y., Shin, S., Jeon, S. Y., Hwang, Y., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00609-7 · Cited by 25
Chen, H., Weng, Z., & Xu, C. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000914 · Cited by 25
Applying Tissue Slice Culture in Cancer Research—Insights from Preclinical Proton Radiotherapy
Suckert, T., Rassamegevanon, T., Müller, J., Dietrich, A., Graja, A., Reiche, M., Löck, S., Krause, M., Beyreuther, E., & von Neubeck, C. (2020) · Cancers · doi:10.3390/cancers12061589 · Cited by 28
Grbovic-Huezo, O., Pitter, K. L., Lecomte, N., Saglimbeni, J. A., Aşkan, G., Holm, M., Melchor, J. P., Chandwani, R., Joshi, S., Haglund, C. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920240117 · Cited by 24
Self-citationSTIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer
Kutschat, A. P., Hamdan, F. H., Wang, X., Wixom, A. Q., Najafova, Z., Gibhardt, C. S., Kopp, W., Gaedcke, J., Ströbel, P., Ellenrieder, V., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2874 · Cited by 25
Hemelryk, A. V., Mout, L., Erkens‐Schulze, S., French, P. J., van Weerden, W. M., & van Royen, M. E. (2021) · Biomolecules · doi:10.3390/biom11111572 · Cited by 27
MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages
Kato, H., Tateishi, K., Fujiwara, H., Nakatsuka, T., Yamamoto, K., Kudo, Y., Hayakawa, Y., Nakagawa, H., Tanaka, Y., Ijichi, H., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.12.254 · Cited by 27
Self-citationApplication Progress of Organoids in Colorectal Cancer
Luo, L., Ma, Y., Zheng, Y., Su, J., & Huang, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.815067 · Cited by 30
Next generation patient derived tumor organoids
Podaza, E., Kuo, H., Nguyen, J., Elemento, O., & Martín, M. L. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.003 · Cited by 26
A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma
Fraunhoffer, N. A., Chanez, B., Teyssedou, C., Bigonnet, M., Bongrain, C., Lermite, É., Pessaux, P., Giannone, F., Chenard, M., Michalak, S., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.11.035 · Cited by 25
Torre-Healy, L. A., Kawalerski, R. R., Oh, K., Chrastecka, L., Peng, X. L., Aguirre, A. J., Rashid, N. U., Yeh, J. J., & Moffitt, R. A. (2023) · Communications Biology · doi:10.1038/s42003-023-04461-6 · Cited by 28
Self-citationGil, D. A., Deming, D. A., & Skala, M. C. (2021) · Journal of Biomedical Optics · doi:10.1117/1.jbo.26.3.036005 · Cited by 24
Liu, X., Gündel, B., Li, X., Liu, J., Wright, A., Löhr, M., Arvidsson, G., & Heuchel, R. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101107 · Cited by 24
Patient-derived tumor models and their distinctive applications in personalized drug therapy
He, J., Zhang, C., Özkan, A., Feng, T., Duan, P., Wang, S., Yang, X., Xie, J., & Liu, X. (2023) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2023.100014 · Cited by 27
Li, P., Huang, M., Li, M., Li, G., Ma, Y., Zhao, Y. X., Wang, X., Zhang, Y., & Shi, C. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03332-8 · Cited by 26
Integration of Organoids With CRISPR Screens: A Narrative Review
Mukhare, R., Gandhi, K., Kadam, A., Raja, A., Singh, A., Madhav, M., Chaubal, R., Pandey, S., & Gupta, S. (2025) · Biology of the Cell · doi:10.1111/boc.70006 · Cited by 26
Palliative chemotherapy in pancreatic cancer—treatment sequences
Abbassi, R., & Algül, H. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.06.09 · Cited by 25
Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
Wu, C. L., Yang, P., Liu, B., & Tang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232464 · Cited by 29
Metadata
- Authors
- Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., Miyabayashi, K., Young, C. M., Patel, H., Ma, M., LaComb, J. F., Palmaira, R. L. D., Javed, A. A., Huynh, J. C., Johnson, M., Arora, K., Robine, N., Shah, M., Sanghvi, R., Goetz, A. B., Lowder, C. Y., Martello, L., Driehuis, E., LeComte, N., Askan, G., Iacobuzio-Donahue, C. A., Clevers, H., Wood, L. D., Hruban, R. H., Thompson, E., Aguirre, A. J., Wolpin, B. M., Sasson, A., Kim, J., Wu, M., Bucobo, J. C., Allen, P., Sejpal, D. V., Nealon, W., Sullivan, J. D., Winter, J. M., Gimotty, P. A., Grem, J. L., DiMaio, D. J., Buscaglia, J. M., Grandgenett, P. M., Brody, J. R., Hollingsworth, M. A., O'Kane, G. M., Notta, F., Kim, E., Crawford, J. M., Devoe, C., Ocean, A., Wolfgang, C. L., Yu, K. H., Li, E., Vakoc, C. R., Hubert, B., Fischer, S. E., Wilson, J. M., Moffitt, R., Knox, J., Krasnitz, A., Gallinger, S., & Tuveson, D. A.
- Affiliations
- Cold Spring Harbor Laboratory (US)
- Johns Hopkins University (US)
- Ontario Institute for Cancer Research (CA)
- Stony Brook University (US)
- Memorial Sloan Kettering Cancer Center (US)
- UC Davis Comprehensive Cancer Center (US)
- New York Genome Center (US)
- Thomas Jefferson University (US)
- SUNY Downstate Health Sciences University (US)
- Royal Netherlands Academy of Arts and Sciences (NL)
- 6Memorial Sloan Kettering Cancer Center, New York, New York.
- Broad Institute (US)
- Hofstra University (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- University of Pennsylvania (US)
- University of Nebraska Medical Center (US)
- Nebraska Medical Center (US)
- University Health Network (CA)
- Weill Cornell Medicine (US)
- 3PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
- Corresponding author
- Tuveson, David A.
- ORCID
- Tiriac, Hervé
- Engle, Dannielle D.
- Plenker, Dennis
- Deschênes, Astrid
- Somerville, Tim D. D.
- Froeling, Fieke E. M.
- Burkhart, Richard A.
- Denroche, Robert E.
- Jang, Gun-Ho
- Miyabayashi, Koji
- Young, C. Megan
- LaComb, Joseph F.
- Javed, Ammar A.
- Huynh, Jasmine C.
- Johnson, Molly
- Arora, Kanika
- Robine, Nicolas
- Sanghvi, Rashesh
- Lowder, Cinthya Y.
- Martello, Laura
- Driehuis, Else
- LeComte, Nicolas
- Clevers, Hans
- Wood, Laura D.
- Hruban, Ralph H.
- Aguirre, Andrew J.
- Wolpin, Brian M.
- Kim, Joseph
- Wu, Maoxin
- Bucobo, Juan Carlos
- Nealon, William
- Winter, Jordan M.
- Gimotty, Phyllis A.
- Grem, Jean L.
- DiMaio, Dominick J.
- Buscaglia, Jonathan M.
- Grandgenett, Paul M.
- Brody, Jonathan R.
- Hollingsworth, Michael A.
- O'Kane, Grainne M.
- Notta, Faiyaz
- Kim, Edward
- Crawford, James M.
- Devoe, Craig
- Ocean, Allyson
- Wolfgang, Christopher L.
- Yu, Kenneth H.
- Li, Ellen
- Vakoc, Christopher R.
- Fischer, Sandra E.
- Wilson, Julie M.
- Moffitt, Richard
- Knox, Jennifer
- Krasnitz, Alexander
- Tuveson, David A.
- Venue
- Cancer Discovery
- Published
- 2018-09-01
- Volume
- 8
- Issue
- 9
- Pages
- 1112-1129
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6125219
- OpenAlex
- W2807088563
- Cited by
- 1,092
- References
- 62
- Citations by year
- 2026: 132 · 2025: 135 · 2024: 147 · 2023: 130 · 2022: 150 · 2021: 168 · 2020: 128 · 2019: 83 · 2018: 16
- FWCI
- 36.76
- Type
- journal article
- Language
- en
- Open access
- green
- pure.knaw.nl
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- HHS | National Institutes of Health (NIH) (5P30CA45508-29, 5P50CA101955-07, P20CA192996-03, 1U10CA180944-04, 5U01CA168409-5, 1R01CA188134-01, 1R01CA190092-04, HHSN26100008)
- Lustgarten Foundation
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- pancreatic cancer, patient-derived organoids, chemotherapy response, chemotherapy response prediction, predictive biomarkers, transcriptomic subtypes, cancer driver genes, gene expression signatures, synchronous metastases, chemotherapy-refractory disease, targeted therapy, precision medicine, adjuvant chemotherapy
- MeSH terms
- Antineoplastic Agents, Drug Screening Assays, Antitumor, Humans, Organoids, Pancreatic Neoplasms, Prospective Studies, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Sequence Analysis, RNA, Drug Resistance, Neoplasm, Gene Expression Profiling, Gene Regulatory Networks, Precision Medicine, Molecular Targeted Therapy, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
